Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-10-14
Schrodinger, Inc.
Schrödinger sells physics-based molecular discovery software to pharma and biotech customers and also monetizes its platform through collaborations, milestones, royalties, and proprietary drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Monetization Is the Real Test
The upside case is that scientific AI expands Schrödinger from specialist modeling software into a deeper discovery workflow system inside large pharma. The stock can work well from here, but only if more platform usage turns into measurably higher account economics.

Analysis

Thesis
Over the next five years, Schrödinger can shift from a specialist modeling vendor to a higher-value discovery workflow system: hosted delivery, Bunsen, and broader program-level monetization should raise wallet share inside large pharma while collaborations and royalties add upside without requiring extreme capital intensity.
Last Economy Alignment
Cheaper cognition helps Schrödinger because more molecular design work moves into software before wet-lab spend, and its physics-based workflows are harder to replace than a thin AI wrapper. The cap on upside is that big pharma may capture part of the productivity gain unless Schrödinger keeps shifting pricing toward throughput, governance, and validated outcomes.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
This is a credible 2x-type setup, not a 10x story. The main driver is deeper monetization of existing enterprise accounts as hosted delivery, Bunsen, and adjacent workflow tools move Schrödinger from expert-user software toward program-level operating infrastructure. I do not need heroic drug pipeline success; I only need sustained software expansion, cleaner revenue recognition after the hosted shift, and modest contribution from collaborations and royalties.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The biggest risk is not that Schrödinger becomes irrelevant; it is that customers use the platform more while paying only a little more. Customer concentration, hosted-delivery reliability, and proof that Bunsen lifts durable account economics are the main gates. If those gates clear, risk falls quickly because the model is not capex-heavy and the balance sheet is still strong.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They sit inside drug discovery workflows where AI should increase the amount of design and simulation done before expensive lab work. The upside comes from owning the workspace and validation layer; the risk is that customers use AI to do more science without paying much more for it.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.43
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case